Navigation Links
Valporic Acid Blocks Latent HIV Replication

Researchers at the University of North Carolina have found that administrating Valporic acid can kill dormant HIV persistent in the infected cells. HAART (Highly Active Antiretroviral Therapy), which is administered to AIDS patients acts by blocking the virus replication and also enhances the immune system // of these patients. But HAART cannot act on the virus, which is present in the latent phase in the cells. Which leads to continuous HAART treatment to affected patients, as the virus may emerge from cells as soon as HAART treatment is stopped. Researchers have found that by co-administration of Valporic acid with HAART leads to better treatment in AIDS patients. Valporic acid, which is used treat bipolar disorders, is found to block the action of Histone Deacetylase 1 (HDAC1), which helps HIV to survive in the latent phase of infection. Valporic acid stops the action of HDAC1 enzyme and breaks the latency of the virus in latent phase.

A clinical study involving 4 HIV patients undergoing HAART therapy where administered Valporic acid for three months, twice daily and the researchers found a reduction of 75% in latent HIV infection in three of the four patients during the Valporic acid treatment. If a larger clinical study is proved of its effective treatment this drug can be used for the eradication of established HIV infection. The patient should be started early HAART treatment followed by HDAC inhibitors or both for treating the latent virus infection.

Dr Chris Gadd, of the UK's Aidsmap, which offers advice on HIV/AIDS to patients and health professionals, said: "The encouraging message from this study is that using an existing, licensed drug is a feasible, although still highly experimental approach to achieving HIV eradication from these viral reservoirs, at least partially. "The study shows that the hypothesis - that the intensification of antiretroviral therapy with a new drug, coupled with the addition of valproate, can reduce the n umbers of resting, infected cells - is feasible.

Source: The Lancet


'"/>




Related medicine news :

1. Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax
2. New Drug Blocks Influenza, Including Bird Flu Virus
3. Latest Weight-Loss Pill Offers Modest Results, Blocks Munchies
4. Sentry Enzyme Blocks Two Paths to Parkinson’s Diseas
5. Treating Latent Herpes With Licorice
6. New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment
7. Detecting Latent Tuberculosis Effective With Blood Tests
8. High Rates of Latent TB Infection Found in Russian Health Workers
9. Acute Measles Supresses HIV Replication
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology: